Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4
Maxim Group analyst Jason McCarthy initiates coverage on Telomir Pharmaceuticals (NASDAQ:TELO) with a Buy rating and announces Price Target of $4.
Share
Why It Matters
An analyst at Maxim Group started following Telomir and said it looks good. When experts start watching a smaller company, it can mean they found something worth paying attention to.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.